IE890126L - Stabilization of cephalosporin derivatives - Google Patents

Stabilization of cephalosporin derivatives

Info

Publication number
IE890126L
IE890126L IE890126A IE12689A IE890126L IE 890126 L IE890126 L IE 890126L IE 890126 A IE890126 A IE 890126A IE 12689 A IE12689 A IE 12689A IE 890126 L IE890126 L IE 890126L
Authority
IE
Ireland
Prior art keywords
cephalosporin derivatives
stabilization
cephalosporin
derivatives
stabilisation
Prior art date
Application number
IE890126A
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of IE890126L publication Critical patent/IE890126L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A stable composition of cephalosporin derivatives obtainable by drying from a joint solution of a cephalosporin derivative as active ingredient and lactose, glucose, sucrose or galactose as stabiliser, and a process for the stabilisation of cephalosporin derivatives are described. [EP0325112A1]
IE890126A 1988-01-18 1989-01-17 Stabilization of cephalosporin derivatives IE890126L (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3801179A DE3801179A1 (en) 1988-01-18 1988-01-18 STABILIZATION OF CEPHALOSPORINE DERIVATIVES BY DRYING WITH A STABILIZER AND STABLE PREPARATION FORMS WITH CEPHALOSPORINE DERIVATIVES

Publications (1)

Publication Number Publication Date
IE890126L true IE890126L (en) 1989-07-18

Family

ID=6345430

Family Applications (1)

Application Number Title Priority Date Filing Date
IE890126A IE890126L (en) 1988-01-18 1989-01-17 Stabilization of cephalosporin derivatives

Country Status (12)

Country Link
EP (1) EP0325112A1 (en)
JP (1) JPH01216996A (en)
KR (1) KR890011894A (en)
CN (1) CN1034670A (en)
AU (1) AU2853989A (en)
DE (1) DE3801179A1 (en)
DK (1) DK19489A (en)
HU (1) HUT49487A (en)
IE (1) IE890126L (en)
IL (1) IL88957A0 (en)
PT (1) PT89464A (en)
ZA (1) ZA89332B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19539574A1 (en) 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Preparations and processes for stabilizing biological materials by means of drying processes without freezing
EP0913177A1 (en) * 1997-11-03 1999-05-06 Roche Diagnostics GmbH Process for producing dry, amorphous products comprising biological active materials by means of convection drying technique, especially spray drying
EP0913178A1 (en) * 1997-11-03 1999-05-06 Boehringer Mannheim Gmbh Process for the manufacture of dry, amorphous products comprising biologically active material by means of convection drying and products obtainable by the process
EP1656930A1 (en) * 2004-11-10 2006-05-17 Basilea Pharmaceutica AG Stabilized freeze-dried formulation for cephalosporin derivatives
CN101590061B (en) * 2009-04-14 2010-09-29 深圳立健药业有限公司 Medicinal composition of cefotetan disodium
ME02854B (en) 2013-03-13 2018-04-20 Theravance Biopharma Antibiotics Ip Llc Hydrochloride salts of an antibiotic compound
KR101935186B1 (en) * 2014-09-04 2019-01-03 시오노기세야쿠 가부시키가이샤 Pharmaceutical preparation comprising cephalosporin having catechol groups

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2017373A1 (en) * 1969-04-15 1971-04-22 Orsymonde S A , Paris Lyophilized products and processes for their manufacture
JPS5132723A (en) * 1974-09-11 1976-03-19 Toyama Chemical Co Ltd YOJOKAIGATACHUSHAYOSEIZAI NO SHINKISEIHO NARABINI SONOYOKAI YOSUI YOEKI
JPS5711909A (en) * 1980-06-23 1982-01-21 Shionogi & Co Ltd Stable freeze-dried preparation of beta-lactam
JPS6045514A (en) * 1983-08-22 1985-03-12 Shionogi & Co Ltd Stable antibacterial lyophilized pharmactical preparation
DE3577656D1 (en) * 1984-07-23 1990-06-21 Lilly Co Eli PHARMACEUTICAL COMPOSITIONS OF CEFTAZIDIM.
JP2690009B2 (en) * 1986-07-10 1997-12-10 エーザイ 株式会社 Cefalosporin injection

Also Published As

Publication number Publication date
DK19489D0 (en) 1989-01-17
DK19489A (en) 1989-07-19
AU2853989A (en) 1989-07-20
DE3801179A1 (en) 1989-07-27
PT89464A (en) 1990-02-08
HUT49487A (en) 1989-10-30
EP0325112A1 (en) 1989-07-26
KR890011894A (en) 1989-08-23
ZA89332B (en) 1989-09-27
CN1034670A (en) 1989-08-16
IL88957A0 (en) 1989-08-15
JPH01216996A (en) 1989-08-30

Similar Documents

Publication Publication Date Title
AU2348988A (en) 4H-1-benzopyran-4-one derivative or its salt, processes for producing the same and pharmaceutical composition comprising the same as active ingredient
HUT58059A (en) Insecticidal composiiton and process for producing its active ingredient, 1-pyridylimidazole derivatives
AU3091489A (en) Piperazine derivative or its salt, process for producing the same and pharmaceutical composition comprising the same as active ingredient
AU4422793A (en) Triazolylthiomethylthio cephalosporin hydrochloride, its crystalline hydrate and the production of the same
EP0345082A3 (en) Enzyme formation suppressing agent
IE891224L (en) Macrolide compositions
NO880182D0 (en) PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE 1, 2-DIHYDRO-3H-INDAZOL-3H-INDAZOL-3-ON DERIVATIVES.
HUT44908A (en) Fungicides comprising triazolyl- or imidazolyl-group-substituted 2,5-dihydrofuran derivatives as active ingredient and process for producing the active ingredient and intermediaries thereof
IE890126L (en) Stabilization of cephalosporin derivatives
HUT62761A (en) Pyridine derivatives, process for producing same and herbicidal compositions comprising such compounds and active ingredient
AU7841891A (en) Process for the preparation of dialkyl pyridine-2,3-dicarboxylates and derivatives thereof from dialkyl dichlorosucciante
AU8087087A (en) Process for the preparation of 5,6 dihydroxyindole and its 3-alkyl derivative; intermediate compounds and its nitrile intermediate compounds
EP0308044A3 (en) Azadirachtin derivative insecticides
HUT47794A (en) Insecticide, acaricide and nematocide compositions containing pyridazinone derivatives as active components and process for producing the active components
CA2092045A1 (en) Erythromycin derivatives, preparation and use thereof
HUT54358A (en) Process for producing substituted 1,3,5-triazinetrione derivatives and medical compositions comprising such compounds as active ingredient
IE880250L (en) Parenteral suspensions
EP0580871A4 (en) Water-soluble cellulose derivative and biocompatible material.
FI893163A0 (en) Process for Preparation of 19-Substituted Progesterone Derivatives Useful as 19-Hydroxylase Inhibitors
EP0365678A4 (en) 2,5,6,7-TETRANOR-4,8-INTER-m-PHENYLENE PGI 2 DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND USE THEREOF.
IE870845L (en) N'-substituted-n,n'-diacylhydrazines
AU4482489A (en) Novel tetrahydropyrimidine derivatives, process for their preparation and insecticides containing same as active ingredients
EP0270692A4 (en) Antiarrhythmic agent
NO168648C (en) ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE NITROGEN CONTAINING DERIVATIVES OF EPIPODOPHYLLOTOXIN GLUCOSIDE DERIVATIVES.
AU2194688A (en) Process for the preparation of crystalline silicates, crystalline metallosilicates and/or derivatives thereof